208 related articles for article (PubMed ID: 24703880)
1. Halofuginone improves muscle-cell survival in muscular dystrophies.
Bodanovsky A; Guttman N; Barzilai-Tutsch H; Genin O; Levy O; Pines M; Halevy O
Biochim Biophys Acta; 2014 Jul; 1843(7):1339-47. PubMed ID: 24703880
[TBL] [Abstract][Full Text] [Related]
2. Halofuginone promotes satellite cell activation and survival in muscular dystrophies.
Barzilai-Tutsch H; Bodanovsky A; Maimon H; Pines M; Halevy O
Biochim Biophys Acta; 2016 Jan; 1862(1):1-11. PubMed ID: 26454207
[TBL] [Abstract][Full Text] [Related]
3. Halofuginone inhibits Smad3 phosphorylation via the PI3K/Akt and MAPK/ERK pathways in muscle cells: effect on myotube fusion.
Roffe S; Hagai Y; Pines M; Halevy O
Exp Cell Res; 2010 Apr; 316(6):1061-9. PubMed ID: 20060825
[TBL] [Abstract][Full Text] [Related]
4. Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone.
Turgeman T; Hagai Y; Huebner K; Jassal DS; Anderson JE; Genin O; Nagler A; Halevy O; Pines M
Neuromuscul Disord; 2008 Nov; 18(11):857-68. PubMed ID: 18672370
[TBL] [Abstract][Full Text] [Related]
5. Hydroxy group requirement for halofuginone-dependent inhibition of muscle fibrosis and improvement of histopathology in the mdx mouse model for Duchenne muscular dystrophy.
Wellner G; Mordechay S; Evans P; Genin O; Pines M; Halevy O
Histol Histopathol; 2019 Jul; 34(7):791-801. PubMed ID: 30628720
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor type-β inhibits Mas receptor expression in fibroblasts but not in myoblasts or differentiated myotubes; Relevance to fibrosis associated to muscular dystrophies.
Cofre C; Acuña MJ; Contreras O; Morales MG; Riquelme C; Cabello-Verrugio C; Brandan E
Biofactors; 2015; 41(2):111-20. PubMed ID: 25809912
[TBL] [Abstract][Full Text] [Related]
7. Differential Effects of Halofuginone Enantiomers on Muscle Fibrosis and Histopathology in Duchenne Muscular Dystrophy.
Mordechay S; Smullen S; Evans P; Genin O; Pines M; Halevy O
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209117
[TBL] [Abstract][Full Text] [Related]
8. Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone.
Huebner KD; Jassal DS; Halevy O; Pines M; Anderson JE
Am J Physiol Heart Circ Physiol; 2008 Apr; 294(4):H1550-61. PubMed ID: 18263710
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of muscle fibrosis and improvement of muscle histopathology in dysferlin knock-out mice treated with halofuginone.
Halevy O; Genin O; Barzilai-Tutsch H; Pima Y; Levi O; Moshe I; Pines M
Histol Histopathol; 2013 Feb; 28(2):211-26. PubMed ID: 23275304
[TBL] [Abstract][Full Text] [Related]
10. Halofuginone and muscular dystrophy.
Pines M; Halevy O
Histol Histopathol; 2011 Jan; 26(1):135-46. PubMed ID: 21117034
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of muscle fibrosis results in increases in both utrophin levels and the number of revertant myofibers in Duchenne muscular dystrophy.
Levi O; Genin O; Angelini C; Halevy O; Pines M
Oncotarget; 2015 Sep; 6(27):23249-60. PubMed ID: 26015394
[TBL] [Abstract][Full Text] [Related]
12. The involvement of collagen triple helix repeat containing 1 in muscular dystrophies.
Spector I; Zilberstein Y; Lavy A; Genin O; Barzilai-Tutsch H; Bodanovsky A; Halevy O; Pines M
Am J Pathol; 2013 Mar; 182(3):905-16. PubMed ID: 23274062
[TBL] [Abstract][Full Text] [Related]
13. A promotive effect for halofuginone on membrane repair and synaptotagmin-7 levels in muscle cells of dysferlin-null mice.
Barzilai-Tutsch H; Dewulf M; Lamaze C; Butler Browne G; Pines M; Halevy O
Hum Mol Genet; 2018 Aug; 27(16):2817-2829. PubMed ID: 29771357
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention.
Zion O; Genin O; Kawada N; Yoshizato K; Roffe S; Nagler A; Iovanna JL; Halevy O; Pines M
Pancreas; 2009 May; 38(4):427-35. PubMed ID: 19188864
[TBL] [Abstract][Full Text] [Related]
15. Focusing on fibrosis: halofuginone-induced functional improvement in the mdx mouse model of Duchenne muscular dystrophy.
McLoon LK
Am J Physiol Heart Circ Physiol; 2008 Apr; 294(4):H1505-7. PubMed ID: 18310507
[No Abstract] [Full Text] [Related]
16. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.
Percival JM; Whitehead NP; Adams ME; Adamo CM; Beavo JA; Froehner SC
J Pathol; 2012 Sep; 228(1):77-87. PubMed ID: 22653783
[TBL] [Abstract][Full Text] [Related]
17. Decrease of myofiber branching via muscle-specific expression of the olfactory receptor mOR23 in dystrophic muscle leads to protection against mechanical stress.
Pichavant C; Burkholder TJ; Pavlath GK
Skelet Muscle; 2016; 6():2. PubMed ID: 26798450
[TBL] [Abstract][Full Text] [Related]
18. Elevated Expression of Moesin in Muscular Dystrophies.
Pines M; Levi O; Genin O; Lavy A; Angelini C; Allamand V; Halevy O
Am J Pathol; 2017 Mar; 187(3):654-664. PubMed ID: 28082118
[TBL] [Abstract][Full Text] [Related]
19. Fibrosis inhibition and muscle histopathology improvement in laminin-alpha2-deficient mice.
Nevo Y; Halevy O; Genin O; Moshe I; Turgeman T; Harel M; Biton E; Reif S; Pines M
Muscle Nerve; 2010 Aug; 42(2):218-29. PubMed ID: 20589893
[TBL] [Abstract][Full Text] [Related]
20. Induction of CCAAT/Enhancer-Binding Protein β Expression With the Phosphodiesterase Inhibitor Isobutylmethylxanthine Improves Myoblast Engraftment Into Dystrophic Muscle.
Lala-Tabbert N; Fu D; Wiper-Bergeron N
Stem Cells Transl Med; 2016 Apr; 5(4):500-10. PubMed ID: 26941360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
